BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, has announced a distribution agreement with Avantor® (NYSE: AVTR), a global leader in mission-critical products and services for the life sciences and advanced technology industries.

康涅狄格州布兰福德（BUSINESS WIRE）--Quantum Si Incorporated（纳斯达克：QSI）（“Quantum Si”，“QSI”或“公司”）是一家蛋白质测序公司™，已宣布与Avantor®（纽约证券交易所：AVTR）达成分销协议，Avantor®是生命科学和先进技术行业关键任务产品和服务的全球领导者。

Through this collaboration, Avantor will distribute Quantum-Si's Next-Generation Protein Sequencing (NGPS) portfolio, providing researchers across all market segments in the U.S. and Canada streamlined access to these innovative proteomics solutions..

通过这次合作，Avantor将分发Quantum Si的下一代蛋白质测序（NGPS）产品组合，为美国和加拿大所有细分市场的研究人员提供这些创新蛋白质组学解决方案的简化访问。。

The distribution agreement enables Avantor to offer Quantum-Si’s protein sequencing technology to a broad range of laboratories focused on proteomics. Quantum-Si’s platform leverages single-molecule sequencing technology, with applications across protein and biomarker identification, antibody characterization, protein barcoding and post-translational modification analysis, to deliver unprecedented insights into protein structure and function, empowering scientists in fields like drug discovery, diagnostics, and clinical research..

该分销协议使Avantor能够为专注于蛋白质组学的广泛实验室提供Quantum Si的蛋白质测序技术。Quantum Si的平台利用单分子测序技术，将其应用于蛋白质和生物标志物鉴定、抗体表征、蛋白质条形码和翻译后修饰分析，为蛋白质结构和功能提供前所未有的见解，为药物发现、诊断和临床研究等领域的科学家提供了力量。。

“By making our portfolio available through Avantor, we are expanding the reach of our Next-Generation Protein Sequencing technology to a wider audience,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “We believe this agreement will allow us to rapidly scale delivery of our innovative solutions to more researchers, accelerating scientific discoveries and advancements in critical research areas.”.

Quantum Si总裁兼首席执行官杰夫·霍金斯（Jeff Hawkins）表示：“通过Avantor提供我们的产品组合，我们正在将下一代蛋白质测序技术的影响力扩大到更广泛的受众。我们相信，这项协议将使我们能够迅速向更多研究人员提供创新解决方案，加速关键研究领域的科学发现和进步。”。

“Avantor’s strong presence in the U.S. and Canada, combined with its digital platforms and the expertise of their life sciences team, will offer Quantum-Si customers direct access to a comprehensive support system for implementing NGPS across diverse research settings,” said Todd Bennett, Chief Commercial Officer of Quantum-Si.

Quantum Si首席商务官托德·贝内特（ToddBennett）表示：“Avantor在美国和加拿大的强大影响力，加上其数字平台及其生命科学团队的专业知识，将为Quantum Si客户提供一个全面的支持系统，用于在不同的研究环境中实施NGP。”。

“This agreement is a significant step forward in scaling our business and expanding our reach, ensuring that our cutting-edge technology is accessible to a wider range of researchers and laboratories.”.

“这项协议在扩大我们的业务规模和扩大我们的业务范围方面迈出了重要的一步，确保我们的尖端技术可供更广泛的研究人员和实验室使用。”。

For more information on Quantum-Si’s technology and research applications, please visit The Protein Sequencing Company™ | Quantum-Si

About Quantum-Si Incorporated

关于Quantum Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Generation Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools.

蛋白质测序公司Quantum Si专注于彻底改变蛋白质组学的发展领域。该公司的Platinum®仪器使下一代蛋白质测序™能够推进蛋白质组学研究，药物发现和诊断，超越现有蛋白质组学工具的可能性。

Learn more at quantum-si.com or follow us on LinkedIn or X..

请访问quantum-si.com了解更多信息，或在LinkedIn或X上关注我们。。

Forward Looking Statements

前瞻性声明

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events.

本新闻稿包括1995年《美国私人证券诉讼改革法案》中“安全港”条款所指的“前瞻性声明”。公司的实际结果可能与其预期、估计和预测不同，因此，您不应将这些前瞻性陈述视为对未来事件的预测。

Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements.

诸如“预期”、“估计”、“项目”、“预算”、“预测”、“预期”、“打算”、“计划”、“可能”、“会”、“可能”、“应该”、“相信”、“预测”、“潜在”、“继续”等词语以及类似表达（或此类词语或表达的负面版本）旨在识别此类前瞻性陈述。

These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements.

这些前瞻性报表包括但不限于公司对未来业绩以及产品和服务的开发和商业化的预期，其预期现金跑道以及2024年全年的财务指导。这些前瞻性陈述涉及重大风险和不确定性，可能导致实际结果与前瞻性陈述中讨论的结果存在重大差异。

Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adopti.

这些因素大多不在公司的控制范围内，很难预测。可能导致此类差异的因素包括但不限于：无法维持公司A类普通股在纳斯达克股票市场的上市；公司盈利增长和管理增长并留住关键员工的能力；公司正在进行的领导层过渡；适用法律法规的变更；公司未来融资的能力；公司产品开发和商业化活动的成功、成本和时间安排；商业化和采用。

About Avantor®

关于Avantor®

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve.

Avantor®是一家财富500强公司，是为生物制药、医疗保健、教育和政府以及先进技术和应用材料行业的客户提供关键任务产品和服务的全球领先供应商。我们的投资组合几乎用于我们服务的行业中最重要的研究、开发和生产活动的每个阶段。

Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For more information, please visit www.avantorsciences.com..

我们的全球足迹使我们能够为超过225000个客户地点提供服务，并使我们能够广泛接触180多个国家的研究实验室和科学家。我们启动科学，创造一个更美好的世界。。。